Bacteria injected into tumors: a new weapon against cancer?
Disease control
Recruiting now
This early-stage trial tests a genetically modified version of the Yersinia enterocolitica bacterium, given alone or with the immunotherapy pembrolizumab, in 100 adults with advanced solid tumors that have no standard treatment options. The goal is to find a safe dose and see if …
Phase: PHASE1, PHASE2 • Sponsor: T3 Pharmaceuticals AG • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC